TAYSHA GENE THERAPIES INC (TSHA) Fundamental Analysis & Valuation

NASDAQ:TSHA • US8776191061

Current stock price

6.4 USD
0 (0%)
At close:
6.4 USD
0 (0%)
After Hours:

This TSHA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TSHA Profitability Analysis

1.1 Basic Checks

  • In the past year TSHA has reported negative net income.
  • In the past year TSHA has reported a negative cash flow from operations.
  • TSHA had negative earnings in each of the past 5 years.
  • TSHA had a negative operating cash flow in each of the past 5 years.
TSHA Yearly Net Income VS EBIT VS OCF VS FCFTSHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of TSHA (-31.75%) is better than 62.40% of its industry peers.
  • TSHA has a Return On Equity of -44.14%. This is in the better half of the industry: TSHA outperforms 65.31% of its industry peers.
Industry RankSector Rank
ROA -31.75%
ROE -44.14%
ROIC N/A
ROA(3y)-50.67%
ROA(5y)-73%
ROE(3y)-105.96%
ROE(5y)-3789.27%
ROIC(3y)N/A
ROIC(5y)N/A
TSHA Yearly ROA, ROE, ROICTSHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -5K -10K -15K

1.3 Margins

  • TSHA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TSHA Yearly Profit, Operating, Gross MarginsTSHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. TSHA Health Analysis

2.1 Basic Checks

  • TSHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TSHA has more shares outstanding
  • The number of shares outstanding for TSHA has been increased compared to 5 years ago.
  • TSHA has a better debt/assets ratio than last year.
TSHA Yearly Shares OutstandingTSHA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
TSHA Yearly Total Debt VS Total AssetsTSHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • TSHA has an Altman-Z score of 8.55. This indicates that TSHA is financially healthy and has little risk of bankruptcy at the moment.
  • TSHA has a Altman-Z score of 8.55. This is in the better half of the industry: TSHA outperforms 79.46% of its industry peers.
  • A Debt/Equity ratio of 0.20 indicates that TSHA is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.20, TSHA is doing worse than 66.67% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 8.55
ROIC/WACCN/A
WACC9.68%
TSHA Yearly LT Debt VS Equity VS FCFTSHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • TSHA has a Current Ratio of 12.23. This indicates that TSHA is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 12.23, TSHA belongs to the top of the industry, outperforming 85.66% of the companies in the same industry.
  • TSHA has a Quick Ratio of 12.23. This indicates that TSHA is financially healthy and has no problem in meeting its short term obligations.
  • TSHA has a Quick ratio of 12.23. This is amongst the best in the industry. TSHA outperforms 85.66% of its industry peers.
Industry RankSector Rank
Current Ratio 12.23
Quick Ratio 12.23
TSHA Yearly Current Assets VS Current LiabilitesTSHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. TSHA Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 5.56% over the past year.
  • Looking at the last year, TSHA shows a quite strong growth in Revenue. The Revenue has grown by 17.28% in the last year.
  • Measured over the past years, TSHA shows a very strong growth in Revenue. The Revenue has been growing by 57.53% on average per year.
EPS 1Y (TTM)5.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
Revenue 1Y (TTM)17.28%
Revenue growth 3Y57.53%
Revenue growth 5YN/A
Sales Q2Q%171.27%

3.2 Future

  • TSHA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.91% yearly.
  • The Revenue is expected to grow by 172.13% on average over the next years. This is a very strong growth
EPS Next Y-22%
EPS Next 2Y-15.41%
EPS Next 3Y3.23%
EPS Next 5Y40.91%
Revenue Next Year-47.05%
Revenue Next 2Y157.51%
Revenue Next 3Y168.23%
Revenue Next 5Y172.13%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TSHA Yearly Revenue VS EstimatesTSHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
TSHA Yearly EPS VS EstimatesTSHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. TSHA Valuation Analysis

4.1 Price/Earnings Ratio

  • TSHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TSHA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TSHA Price Earnings VS Forward Price EarningsTSHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TSHA Per share dataTSHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.41%
EPS Next 3Y3.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TSHA Dividend Analysis

5.1 Amount

  • No dividends for TSHA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TSHA Fundamentals: All Metrics, Ratios and Statistics

TAYSHA GENE THERAPIES INC

NASDAQ:TSHA (4/24/2026, 5:31:18 PM)

After market: 6.4 0 (0%)

6.4

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19
Earnings (Next)05-13
Inst Owners95.41%
Inst Owner Change0.54%
Ins Owners1.18%
Ins Owner Change4.84%
Market Cap1.84B
Revenue(TTM)9.77M
Net Income(TTM)-109.00M
Analysts85
Price Target11.8 (84.38%)
Short Float %16.54%
Short Ratio16.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.21%
Min EPS beat(2)-0.01%
Max EPS beat(2)18.43%
EPS beat(4)2
Avg EPS beat(4)6.16%
Min EPS beat(4)-9.04%
Max EPS beat(4)18.43%
EPS beat(8)5
Avg EPS beat(8)11.61%
EPS beat(12)8
Avg EPS beat(12)86.81%
EPS beat(16)10
Avg EPS beat(16)66.34%
Revenue beat(2)1
Avg Revenue beat(2)42.32%
Min Revenue beat(2)-100%
Max Revenue beat(2)184.64%
Revenue beat(4)3
Avg Revenue beat(4)39.6%
Min Revenue beat(4)-100%
Max Revenue beat(4)184.64%
Revenue beat(8)5
Avg Revenue beat(8)15.27%
Revenue beat(12)9
Avg Revenue beat(12)55.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.19%
PT rev (3m)7.28%
EPS NQ rev (1m)1.9%
EPS NQ rev (3m)1.9%
EPS NY rev (1m)5.48%
EPS NY rev (3m)8.58%
Revenue NQ rev (1m)-57.5%
Revenue NQ rev (3m)-57.5%
Revenue NY rev (1m)-22.73%
Revenue NY rev (3m)-19.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 188.12
P/FCF N/A
P/OCF N/A
P/B 7.45
P/tB 7.45
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS0.03
BVpS0.86
TBVpS0.86
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -31.75%
ROE -44.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.67%
ROA(5y)-73%
ROE(3y)-105.96%
ROE(5y)-3789.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.45%
Cap/Sales 7.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.23
Quick Ratio 12.23
Altman-Z 8.55
F-Score4
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)125.57%
Cap/Depr(5y)1052.31%
Cap/Sales(3y)12.36%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.29%
EPS Next Y-22%
EPS Next 2Y-15.41%
EPS Next 3Y3.23%
EPS Next 5Y40.91%
Revenue 1Y (TTM)17.28%
Revenue growth 3Y57.53%
Revenue growth 5YN/A
Sales Q2Q%171.27%
Revenue Next Year-47.05%
Revenue Next 2Y157.51%
Revenue Next 3Y168.23%
Revenue Next 5Y172.13%
EBIT growth 1Y-27.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.26%
EBIT Next 3Y25.7%
EBIT Next 5YN/A
FCF growth 1Y-14.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-14.61%
OCF growth 3YN/A
OCF growth 5YN/A

TAYSHA GENE THERAPIES INC / TSHA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of TAYSHA GENE THERAPIES INC (TSHA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to TSHA.


Can you provide the valuation status for TAYSHA GENE THERAPIES INC?

ChartMill assigns a valuation rating of 0 / 10 to TAYSHA GENE THERAPIES INC (TSHA). This can be considered as Overvalued.


How profitable is TAYSHA GENE THERAPIES INC (TSHA) stock?

TAYSHA GENE THERAPIES INC (TSHA) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for TSHA stock?

The Earnings per Share (EPS) of TAYSHA GENE THERAPIES INC (TSHA) is expected to decline by -22% in the next year.